A Controllable Inflammatory Response and Temporary Abnormal Coagulation in Moderate Disease of COVID-19 in Wuhan, China

Yuchen Liua, c, Xiaohong Zhangb, c, Jialu Qiaoa, Ruyu Gongb, Qiang Youa, Jian Suna, Wei Liu, Binlian Suna, d

Abstract

Background: The coronavirus disease 2019 (COVID-19) is now a worldwide challenge for public health. Among 7 million patients, about 80% present mild to moderate disease, but studies dedicate to these patients are actually scarce. The aim of our study is to clarify the characteristics of laboratory test index of COVID-19 patient with moderate symptoms during the first wave of the pandemic in Wuhan, China.

Methods: In this retrospective cohort study, we included 107 adult inpatients with confirmed moderate disease of COVID-19 from the Affiliated Hospital of Jianghan University during February and early March 2020. All of these patients were recovered from COVID-19 and discharged from hospital. Demographic, clinical, and laboratory data of admission and discharge were extracted from electronic medical records and analyzed using SPSS, as well as among young, middle age and elderly people.

Results: The median age of this cohort of patients was 56.0 years. And the median hospitalization time was 16 days. Common clinical manifestations included fever, cough, asthenia and shortness of breath. On admission, laboratory results showed normal or increased neutrophil ratio, low lymphocyte count, decreased hemoglobin level, and increased inflammatory indicators (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)); and some patients were complicated with coagulation disorder and myocardial damage. Furthermore, patients older than 60 years had statistically higher CRP, ESR and fibrinogen level. As the health condition was improved at discharge, the median level of most laboratory results were in the normal range except hemoglobin and related blood cell count, as well as inflammatory indicator ESR. And patients older than 60 years showed slower recovery on coagulation parameters when compared to younger patients.

Conclusions: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces a controllable inflammatory response in moderate disease of COVID-19 in Wuhan, China. Since patients older than 60 years had higher inflammatory state and more dysregulated coagulation condition, it might be essential to closely assess their illness.

Keywords: COVID-19; Moderate disease; Clinical feature; Laboratory findings; Inflammatory

Introduction

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China in December 2019 [1, 2], and now spread all over the world. Its infection in human mainly appears as acute respiratory syndrome, sometimes along with digestive and nervous disorders [3, 4]. The outbreak of this coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Globally, as of June 28, 2020, there have been 9,843,073 confirmed cases including 495,760 deaths [5].

A large cohort study showed the spectrum of COVID-19 that among 44,415 patients, 81% had mild symptom, 14% had severe disease, and 5% were in critical condition [6]. Naturally most studies about COVID-19 focus on the severe and critical cases, although more than 80% of COVID-19 patients show mild to moderate symptoms. It should be equally important to understand the average degree of SARS-CoV-2 infection, especially if this virus would become another endemic virus in communities like the influenza virus.

Our study describes 107 patients that were admitted in a designated hospital in Wuhan, the Affiliated Hospital of Jianghan University (the sixth hospital of Wuhan city) during February and early March 2020. These patients showed moderate symptom of COVID-19, and were confirmed both by
SARS-CoV-2 RNA test and chest radiography. And they were all discharged from hospital after recovery. The aim of our study is to clarify the characteristics of laboratory test index of COVID-19 patient with moderate symptoms during the first wave of the pandemic in Wuhan. These findings may help us extend our understanding of the pathogenicity in SARS-CoV-2 infection.

Materials and Methods

Patients

This retrospective cohort study included adult patients (≥ 18 years old) with confirmed COVID-19 admitted to the Affiliated Hospital of Jianghan University (the sixth hospital of Wuhan city) in Wuhan from February 1 to March 5, 2020. According to WHO interim guidance [7], 107 patients with moderate disease of COVID-19 on admission were enrolled in this study; they showed clinical signs of pneumonia (fever, cough, dyspnea, fast breathing) but no signs of severe pneumonia, including oxygen saturation (SpO₂) ≥ 90% on room air. All the patients were confirmed by SARS-CoV-2 RNA test in respiratory secretions for twice, as well as by ground-glass opacities or bilateral pulmonary infiltration showed in chest computed tomography (CT) scan. During hospitalization, patients were kept in regular wards without intensive cares or invasive mechanical ventilation. They received supportive therapy, effective oxygen therapy, antiviral agent and, if necessary, antibiotics. Patients were discharged from hospital when the following criteria were met: body temperature normal for more than 3 days, respiratory symptoms significantly improved, pulmonary imaging significantly improved on CT scan, and SARS-CoV-2 RNA tests showed negative for twice. This study was approved by the Ethics Committee of School of Medicine of Jianghan University (Wuhan, China). This study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.

Data collections

The laboratory tests including blood routine, biochemistry, coagulation parameters, and cardiac injury biomarkers were performed in patients on admission and during the hospitalization. The demographic and clinical information, laboratory results, and outcome data were finally collected from electronic medical records.

Statistical analysis

Continuous variables were expressed as median (interquartile range (IQR)) and compared with the one-way analysis of variance (ANOVA) test between different age groups. A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were done using SPSS (version 19.0, IBM).

Results

Patient demographics and characteristics

A total of 107 patients with moderate disease of COVID-19 were recruited. The demographic and clinical characteristics

| Table 1. Demographics and Clinical Characteristics of Patients on Admission (N = 107) |
|---------------------------------|----------------------------------|
| Age (median (IQR), year)        | 56 (43.5 - 65.0)                |
| Sex                             |                                  |
| Male                            | 45 (42%)                         |
| Female                          | 62 (58%)                         |
| Hospitalization days (median (IQR), day) | 16 (13 - 20.5)                |
| Medical history                 |                                  |
| Hypertension                    | 31 (29%)                         |
| Diabetes                        | 6 (5.6%)                         |
| Heart disease                   | 10 (9.3%)                        |
| Cancer                          | 3 (2.8%)                         |
| Other respiratory disease       | 6 (5.6%)                         |
| Kidney disease                  | 6 (5.6%)                         |
| Liver disease                   | 6 (5.6%)                         |
| Neurological disease            | 1 (0.9%)                         |
| Thyroid disease                 | 2 (1.9%)                         |
| Others                          | 8 (7.5%)                         |
| Symptoms                        |                                  |
| Fever                           | 84 (78.5%)                       |
| Cough                           | 63 (58.9%)                       |
| Sputum production               | 18 (16.8%)                       |
| Nose obstruction, rhinorrhea    | 2 (1.9%)                         |
| Shortness of breath             | 32 (29.9%)                       |
| Headache                        | 5 (4.7%)                         |
| Chest pain                      | 2 (1.9%)                         |
| Myalgia                         | 10 (9.3%)                        |
| Asthenia                        | 35 (32.7%)                       |
| Vomiting                        | 3 (2.8%)                         |
| Diarrhea                        | 12 (11.2%)                       |
| Signs                           |                                  |
| Respiratory rate (median (IQR), bpm) | 23 (21 - 30)                  |
| Heart rate (median (IQR), bpm)  | 88 (82.5 - 98)                   |
| SpO₂ < 93%                      | 27 (25%)                         |

Data are median (IQR), n (%), or n/N (%). IQR: interquartile range; SpO₂: oxygen saturation.
Clinical Features of Moderate COVID-19

Table 2. Summary of Laboratory Findings on Admission and at Discharge

| Laboratory index | Normal range | Results on admission | Results at discharge |
|------------------|--------------|----------------------|----------------------|
|                  | Median (IQR) | Patient (%)          | Median (IQR)         | Patient (%)          |
| Neutrophil count, × 10^9/L | 1.8 - 6.3 | 3.4 (2.5 - 4.2) | 8%↑ | 3.1 (2.5 - 3.8) | 4%↑ |
| Neutrophil ratio, % | 40.0 - 75.0 | 67.7 (60.1 - 75.8) | 26%↑ | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte count, × 10^9/L | 1.1 - 3.2 | 1.0 (0.8 - 1.4) | 56%↓ | 1.4 (1.1 - 1.7) | 23%↑ |
| Lymphocyte ratio, % | 20.0 - 50.0 | 22.1 (16.4 - 29.7) | 39%↓ | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 - 5.1 | 3.8 (3.5 - 4.2) | 51%↓ | 3.8 (3.4 - 4.0) | 52%↓ |
| Hemoglobin, g/L | 115.0 - 150.0 | 113 (103 - 127) | 56%↓ | 112 (101.5 - 120) |
| Lymphocyte count, × 10^9/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Neutrophil ratio, % | 67.7 (60.1 - 75.8) | 67.7 (60.1 - 75.8) | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte ratio, % | 22.1 (16.4 - 29.7) | 22.1 (16.4 - 29.7) | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Hematocrit, % | 35.0 - 45.0 | 34.3 (32.2 - 38.3) | 39%↓ | 34.1 (31.5 - 36.8) | 23%↓ |
| Lymphocyte count, × 10^9/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Neutrophil ratio, % | 67.7 (60.1 - 75.8) | 67.7 (60.1 - 75.8) | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte ratio, % | 22.1 (16.4 - 29.7) | 22.1 (16.4 - 29.7) | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Hematocrit, % | 35.0 - 45.0 | 34.3 (32.2 - 38.3) | 39%↓ | 34.1 (31.5 - 36.8) | 23%↓ |
| Lymphocyte count, × 10^9/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Neutrophil ratio, % | 67.7 (60.1 - 75.8) | 67.7 (60.1 - 75.8) | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte ratio, % | 22.1 (16.4 - 29.7) | 22.1 (16.4 - 29.7) | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Hematocrit, % | 35.0 - 45.0 | 34.3 (32.2 - 38.3) | 39%↓ | 34.1 (31.5 - 36.8) | 23%↓ |
| Lymphocyte count, × 10^9/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Neutrophil ratio, % | 67.7 (60.1 - 75.8) | 67.7 (60.1 - 75.8) | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte ratio, % | 22.1 (16.4 - 29.7) | 22.1 (16.4 - 29.7) | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Hematocrit, % | 35.0 - 45.0 | 34.3 (32.2 - 38.3) | 39%↓ | 34.1 (31.5 - 36.8) | 23%↓ |
| Lymphocyte count, × 10^9/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |
| Neutrophil ratio, % | 67.7 (60.1 - 75.8) | 67.7 (60.1 - 75.8) | 62.0 (56.4 - 66.6) | 3%↑ |
| Lymphocyte ratio, % | 22.1 (16.4 - 29.7) | 22.1 (16.4 - 29.7) | 26.8 (22.9 - 31.9) | 13%↓ |
| Red blood cell count, × 10^{12}/L | 3.8 (3.5 - 4.2) | 3.8 (3.4 - 4.0) | 49%↓ | 46%↓ |

Data are median (IQR) or n/N (%). The normal level of NT-proBNP is increased with age. Three normal ranges for different age groups are listed, and results are presented accordingly. ↑For increased blood level. ↓For decreased blood level. hsCRP: high sensitive C-reactive protein; ESR: erythrocyte sedimentation rate; FDP: fibrinogen degradation product; NT-proBNP: N-terminal prohormone brain natriuretic peptide; hs-cTnI: high sensitive cardiac troponin I; CK: creatine kinase; LDH: lactose dehydrogenase; IQR: interquartile range; NA: not applicable.

of these patients are shown in Table 1. Of these patients (62 females and 45 males), the median age at disease onset was 56 years (range: 20 - 92 years), with 40 patients (37%) older than 60 years. Most patients had fever (78.5%) and cough (58.9%) as their first symptoms; some also had asthenia (32.7%), shortness of breath (29.9%), sputum production (16.8%) and diarrhea (11.2%). For the underlying diseases, hypertension (29%), heart disease (9.3%) and diabetes (5.6%) were the most common in medical histories of these patients. On admission, the vital signs of patients were also recorded. Notably, although the SpO₂ of all the patients were ≥ 90% at room air, 25% of patients were ≤ 93%. Patients received symptomatic and pneumonia treatments in hospital; and the median of their hospitalization were 16 days (IQR: 13 - 20).

Whole blood cell counting findings

The whole blood cell counting was monitored for all the patients on admission and during their hospitalization (median values showed in Table 2). The white blood cell counts were generally in the normal range, whereas 56% of patients (60 of 107 patients) showed lymphopenia (lymphocyte count < 1.1 × 10^9/L, Table 2). Among patients showed lymphopenia, 57% (34 of 60) had a decrease by less than 30% (lymphocyte count
Figure 1. Illustration of percentage changes of laboratory index according to number of patients. Data are presented as number of patients that had changed level in laboratory assessments. (a) Decreased lymphocyte count on admission and at discharge. (b) Decreased hemoglobin level on admission and at discharge. (c) Increased CRP level on admission and at discharge. (d) Increased ESR level on admission and at discharge. (e) Increased fibrinogen level on admission and at discharge. (f) Increased D-dimer level on admission and at discharge. (g) Increased FDP level on admission and at discharge. In for the data collected on admission, out for data collected at discharge. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FDP: fibrinogen degradation product.
Table 3. Statistically Significant Biomarkers on Admission and at Discharge With Different Ages

|                | < 45 (n = 29) | 45 - 60 (n = 38) | > 60 (n = 40) |
|----------------|--------------|-----------------|--------------|
| CRP (in)       | 7.2 (0.7 - 53.2) | 15.1 (2.5 - 44.3) | 51.9 (6.5 - 94.4)a |
| ESR (in)       | 35.0 (23.0 - 65.0) | 53.0 (32.5 - 90.5) | 87.5 (56.0 - 107.3)a |
| ESR (out)      | 23.0 (21.0 - 46.0) | 42.0 (25.0 - 63.0) | 71.0 (34.5 - 98.3) |
| Fibrinogen (in)| 3.6 (2.2 - 4.7) | 4.1 (2.8 - 4.6) | 4.4 (3.5 - 5.3) |
| FDP (out)      | 1.7 (1.4 - 2.3) | 1.8 (1.4 - 2.2) | 2.9 (1.9 - 4.1) |
| D-dimer (out)  | 0.3 (0.2 - 0.4) | 0.3 (0.2 - 0.4) | 0.49 (0.32 - 0.82) |
| CK             | 79.0 (50.0 - 161.0) | 78.5 (33.3 - 135.3) | 49.0 (30.8 - 79.8) |

Data are expressed with the median (IQR). P values comparing different age groups are from one-way ANOVA. aP < 0.05 for 45 - 60 group and < 45 group vs. > 60 group has statistical difference. bP < 0.05 for < 45 group vs. > 60 group has statistical difference. In for the data collected on admission, out for data collected at discharge. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; FDP: fibrinogen degradation product; CK: creatine kinase; IQR: interquartile range.

> 0.8 × 10^9/L; Fig. 1a) while 8% (five of 60) of them showed a decrease by more than 50% (lymphocyte count < 0.5 × 10^9/L; Fig. 1a). Twenty-three percent (23 of 98) of patients (Table 2) still had lymphopenia when they were discharged from hospital, and the decrease was limited for most (Fig. 1a). The change of neutrophil count affects fewer patients on admission, 8% of (nine of 107) patients showed neutrophilia (neutrophil count > 6.3 × 10^9/L, Table 2) and 12% (13 of 107) patients had neutropenia (neutrophil count < 3.5 × 10^9/L, Table 2). However, neutrophil ratio was augmented in 26% (28 of 107) of patients (neutrophil ratio > 75%, Table 2), and the maximum increase was about 20%. This ratio appeared to be in the normal range for most patients at discharge. Therefore, the main change in white blood cell counts for patients with moderate COVID-19 was the decrease of lymphocyte. And as the health condition improved at discharge, lymphocyte count also gradually increased to normal level.

The data showed that more than 50% of all patients had declined level of red blood cell count (55 of 107), hemoglobin (52 of 107) and hematocrit (60 of 107) (Table 2); and four female patients were in severe condition (hemoglobin < 90 g/L, Fig. 1b). When discharged from hospital, 50% (45 of 98) of patients still had these decreases (Table 2). The four female patients mentioned above had their hemoglobin increased to over 90 g/L. However, one female of 70 years had less than 90 g/L hemoglobin and that was less than earlier result. Furthermore, there were five more male patients had hemoglobin declined at discharge (Fig. 1b). These results suggested that SARS-CoV-2 infection may be accompanied by oxygen transport defect in red blood cells.

As for the platelet counting on admission, 7% of patients (seven of 107) had decreased platelet level (platelet count < 125 × 10^9/L, Table 2), and 15% (16 of 107) had increased level (platelet count > 350 × 10^9/L, Table 2). At discharge, most patients showed platelet level in the normal range (Table 2).

Inflammatory biomarkers

Inflammatory biomarkers were also examined on admission and during hospitalization, such as erythrocytes sedimentation rate (ESR), C-reactive protein (CRP) and procalcitonin (PCT). For most patients, PCT levels were in the normal range (data not shown). For CRP, the median value was 16.3 mg/L (IQR: 2.9 - 62.7) among 105 patients on admission (Table 2), and patients older than 60 years had significantly higher level (Table 3). To be specific, CRP levels in serum were increased (CRP > 8 mg/L, Table 2) in 60% of patients (63 of 105), and 40% (42 of 105) showed an increase by more than 400% (CRP > 40 mg/L, Fig. 1c). At discharge, only 21% (18 of 87, Table 2) had elevated level of CRP, and the increased level did not exceed 40 mg/L except for one patient (Fig. 1c).

Levels of ESR were increased in 89% of patients (91 of 102, ESR > 20 mm/h, Table 2), and 59% (60 of 102, Fig. 1d) had an increase exceeding 50 mm/h. Similar to CRP, patients older than 60 years had statistically higher ESR level (Table 3). The median value of ESR on admission was 64 mm/h (IQR: 34.0 - 94.5), while the value improved to 50 mm/h (IQR: 24.0 - 80.0) at discharge (Table 2). There were still 36 patients had ESR level more than 50 mm/h in serum (Fig. 1d).

Coagulation parameters

The coagulation parameters were examined on admission for 103 patients. Eighty percent of patients (82 of 103, Table 2) had normal serum levels of D-dimer on admission. Among the 20% of patients (21 of 103) who had increased D-dimer level (D-dimer > 1 mg/L, Table 2), eight showed an increase by more than 100% (D-dimer > 2 mg/L, Fig. 1f). At discharge, 7% of patients (seven of 94) still had abnormal level of D-dimer, though the results were very close to the normal range. The fibrinogen level, on the other hand, had increased in 51% of patients (53 of 103, fibrinogen > 4 mg/L, Table 2) and decreased in 14% (14 of 103, fibrinogen < 2 mg/L). Specifically, 10% patients (10 of 103) had an increase of fibrinogen level by more than 50% (fibrinogen > 6 mg/L, Fig. 1e), while most decreases were slight. Furthermore, when compared to patients younger than 45 years, fibrinogen level on admission was significantly higher in the patients older than 60 years (Table 3). At discharge, only seven patients still showed high level of fibrinogen (Fig. 1e). Fibrinogen degradation product (FDP) was also
patients were complicated with coagulation disorder and myo-
creased inflammatory indicators (ESR and CRP); and some
ratio, low lymphocyte count, decreased hemoglobin level, in-
characteristics on admission: normal or increased neutrophil
patients with moderate disease of COVID-19 had common
different clinical outcomes. (type B) to Europe (type C) [13], which could contribute to
Wuhan. Also, the virus is phylogenetically distinct from Asia
be neglected during the first wave of SARS-CoV-2 infection in
studies in Asia [10, 11], patients mainly present fever (78.5%),
as other risk factors [9]. Similar to other study, 5.6% of pa-
tion can suppress the level of lymphocyte. Therefore, closely
monitoring lymphocyte counts could be one of the best meth-
ods when we evaluate the outcome of moderate patients.

However, these biomarkers were not all specific to COV-
ID-19. Similar to other virus infections including SARS [16]
and H1N1 influenza [17], the neutrophil count was mostly
normal in mild to moderate patients, while lymphocyte count
was significantly decreased. As the major antiviral cells, lym-
phocyte count declined down to 0.27 × 10^9/L in this cohort on
admission. After receiving antiviral and supportive treat-
ment, the lymphocyte counts increased among all the patients
at discharge. Previous study found that lymphocyte counts
would continually decrease in severe and critical COVID-19
patients [4]. These results suggested that SARS-CoV-2 infec-
tion can suppress the level of lymphocyte. Therefore, closely
monitoring lymphocyte counts could be one of the best meth-
ods when we evaluate the outcome of moderate patients.

The blood routine results also showed that about 50% of
patients had low level of hemoglobin, red blood cell, and hem-
atocrit, and the condition was not improved at discharge. Pre-
vious studies also reported that 51% of 99 patients had hemo-
globin below the normal range [18], and the hemoglobin level
of severe patients was lower, although the difference was not
statistically significant [3]. There might be two explanations.
First, the inflammatory state caused by infection may interfere
with erythrocyte/bone marrow metabolism and iron regulation
[19], and eventually result in a decline of hemoglobin and red
blood cell. Second, patients could suffer from anemia for some
time, and appear more vulnerable to SARS-CoV-2 infection.
Once infected, however, correction of anemia could not benefit
from all the symptoms of COVID-19 and psychological stress-
es. The decrease of functioning hemoglobin may contribute to
hypoaxia, and further aggravate the disease in severe cases.

Examination of inflammatory biomarkers found that PCT
was in the normal range for moderate patients, while CRP and
ESR were increased in 60% and 90% of patients on admission,
respectively. Other studies including mild to moderate disease
showed heterogeneous results [20], and found 33% (three of
10) or 100% (30 of 30) of patients had increased level of CRP
[21, 22]. Thus, SARS-CoV-2 infection is involved with the disorder of inflammatory response. Furthermore, we find that
the increase of both CRP and ESR were correlated with pa-
tient’s age, which may indicate that high inflammatory state
and more severe pneumonia present more often in elderly people. In addition, the increase of CRP level was more transient, as it returned to normal range in most people when they were discharged from hospital. Nevertheless, it took more time for ESR to return to normal level, especially for patients older than 60 years. Certainly, elder people would need more time to recover and to metabolize the extra inflammatory biomarkers.

Abnormal coagulation condition is known as associated with poor prognosis of COVID-19. In particular, serum level of D-dimer and FDP were significantly higher in lethal cases [23]. Other coronavirus infection such as SARS and Middle East respiratory syndrome (MERS) showed similar increased coagulation activities in severe cases [24, 25]. The possible mechanism is that local inflammatory response induced by cytokine responses stimulates coagulation cascade and hemodynamic changes [26, 27]. In patients with moderate COVID-19, we found about 50%, 30% and 20% presented increased level in fibrinogen, FDP and D-dimer on admission, respectively. And when compared to young people, patients older than 60 years tend to have higher levels of these coagulation parameters. Certainly, the hemodynamics and endothelial conditions are more complicate in elder people. Furthermore, SARS-CoV-2 infection as well as the inflammatory response it induced could deteriorate the existed dysregulation. As the health condition improved at discharge, these parameters decreased to normal ranges for most patients. Yet again, patients over 60 years had significantly higher level of fibrin degradation products. In the meantime, we found that the platelet level had no obvious decrease in most patients with moderate disease. Therefore, as reported previously, thrombocytopenia happens more often in severe and critical patients [28], while abnormal coagulation condition is slight and temporary in moderate patients.

The receptor of SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2) is expressed in myocardial cells and vascular endothelial cells [29]. It is possible that heart dysfunction is directly targeted by virus infection, hence early evaluation and continued monitoring of cardiac damage are important [30]. We systematically examined the cardiac function biomarkers on admission. CK-MB and cTnL had no obvious change in these moderate patients, while about 10% of patients showed increased NT-proBNP. Furthermore, we only found two patients still had NT-proBNP higher than normal range at discharge, indicating that moderate patients had little cardiac complication.

This study provides us more information about moderate COVID-19, but still has some limitations. First, this is a relatively small, single-center study. Second, due to the retrospective study design, a few laboratory tests were not done in all patients. In addition, several patients were hospitalized during a short period that some tests were not re-examined before they were discharged. Third, we do not possess any viral kinetic data in these patients, further studies are necessary to elucidate the correlation between viral load and laboratory changes.

In this ongoing pandemic, 40% of infected people showed moderate disease [7], it is important to understand more about this moderate spectrum of disease to settle into a long-term problem. We conducted a cohort study of 107 adult patients with moderate disease of COVID-19 in Wuhan, China. Based on the clinical characteristics, we conclude that SARS-CoV-2 infection inhibits the immune system of patients, and induces a controllable inflammatory response in moderate COVID-19. Elderly patients have higher inflammatory state and more dysregulated coagulation condition. It is essential to closely assess their condition for a better clinical management.

Acknowledgments

This study was supported by the Natural Science Foundation of China (31670167), Hubei Province Department of Education Science and Technology Project (B2019232) and the Wuhan Municipal Education Bureau Project (2019003).

Financial Disclosure

There are no financial conflicts of interest to disclose.

Conflict of Interest

All authors declare no competing interests.

Informed Consent

All subjects provided written informed consent.

Author Contributions

YL, XZ and BS designed and performed the study. YL and BS drafted the manuscript and did critical editing. XZ and RG were involved in data collection; YL, JQ, QY, JS and WL analyzed the data. BS carefully supervised this manuscript preparation and writing.

Data Availability

All data used in the study are available from the corresponding author by request. Although some data confidential in nature may only be provided with restrictions.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-544.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang
L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
5. WHO. Coronavirus disease (COVID-19) Situation Report - 160. Available from: https://www.who.int/docs/sitrep-160.pdf?sfvrsn=2fe1c658_2.
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
7. WHO. Clinical management of COVID-19. Available from: https://www.who.int/publications-detail/clinical-management-of-covid-19.
8. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-e18.
9. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25.
10. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-583.
11. Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol. 2020.
12. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, Huet K, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020.
13. Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020;117(17):9241-9243.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
15. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis. 2020;95:304-307.
16. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986-1994.
17. Cheng Y, Zhao H, Song P, Zhang Z, Chen J, Zhou YH. Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. J Infect Public Health. 2019;12(6):878-883.
18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
19. Caveazzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020;10(2):1271.
20. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020;96:467-474.
21. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-2629.
22. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, Liu W, et al. The laboratory tests and host immunity of COVID-19 patients with different severity of illness. JCI Insight. 2020;5(10).
23. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
24. Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, Chan PK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358-1362.
25. Al-Abdallat MM, Payne DC, Alqasrawi S, Tohme RA, Abedi GR, Al Nsour M, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225-1233.
26. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474.
27. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
28. Wuhan, China. JAMA. 2020;323(11):1061-1069.
29. Al-Abdallat MM, Payne DC, Alqasrawi S, Tohme RA, Abedi GR, Al Nsour M, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis. 2014;59(9):1225-1233.
30. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-474.
31. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
32. Wuhan, China. JAMA. 2020;323(11):1061-1069.